Zusammenfassung
Mittels Positronen-Emissions-Tomografie (PET) bzw. Single-Photonen-Emissions-Computer-Tomografie (SPECT) und radioaktiven Markern können Veränderungen auf molekularer Ebene in vivo dargestellt werden. So lässt sich mittels Dopamin-Transporter-SPECT die Degeneration nigrostriataler dopaminerger Projektionen bei Patienten mit einer Parkinson-Krankheit (Morbus Parkinson, MP) sensitiv erfassen. Diese Verfahren haben jedoch nicht nur zum Verständnis der Pathophysiologie des MP beigetragen, sondern bieten mittlerweile in Fällen schwieriger differenzialdiagnostischer Entscheidungen eine valide Hilfe in der klinischen Routine, so zum Beispiel in der Abgrenzung des MP vom essenziellen Tremor, von einem arzneimittelinduzierten Parkinson-Syndom (PS), in der Differenzialdiagnostik atypischer PS bzw. in der Unterscheidung einer Demenz vom Lewy-Körperchen-Typ und einer Alzheimer-Demenz. Der vorliegende Artikel gibt eine Übersicht zur diagnostischen Wertigkeit der Dopamin-Transporter- und -D2 -Rezeptor-SPECT in Klinik und Praxis unter Berücksichtigung weiterer bildgebender Verfahren.
Abstract
By means of positron emission tomography (PET) or, respectively, single photon emission computed tomography (SPECT) with labelled markers, changes at the molecular level can be demonstrated in vivo. For example, dopamine transporter SPECT can sensitively detect the degeneration of nigrostriatal dopaminergic projections in patients with Parkinson's disease (PD). However, these procedures have not only contributed to our understanding of the pathophysiology of PD but also now offer a valid aid in difficult differential diagnostic decisions in clinical routine. Some such examples are the delineation of PD from essential tremor, from a drug-induced Parkinsonian syndrome (PS), in the differential diagnosis of atypical PS or for distinguishing between dementia of the Lewy body type and one of Alzheimer's disease. The present article presents a review of the diagnostic utility of dopamine transporter and D2-receptor SPECT in clinical routine with consideration of other imaging procedures.
Schlüsselwörter
Parkinson-Syndrom - Dopamin - Dopamin-Transporter - SPECT - nuklearmedizinische Bildgebung
Key words
Parkinsonian syndrome - dopamine - dopamine transporter - SPECT - radionuclide imaging
Literatur
123 I-FP-β-CIT versus 99m Tc-TRODAT-1.
Eur J Nucl Med Mol Imaging.
2004;
31
1119-1127
123 I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms.
Synapse.
2008;
62
62-69
2 -Rezeptor-SPECT bei Erkrankungen der Basalganglien.
Nuklearmediziner.
2007;
30
195-203
123 I]FP-CIT SPECT in early-onset parkin disease.
Neurology.
2004;
63
2097-2103
123 I-FP-CIT SPECT striatal uptake.
Mov Disord.
2000;
15
692-698
123 I-β-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis.
Arch Neurol.
2004;
61
1224-1229
123 I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes.
Mov Disord.
2004;
19
1175-1182
123 I-ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study.
Mov Disord.
2007;
22
2346-2351
123 I]β-CIT SPECT in clinical practice?.
J Neurol Neurosurg Psychiatry.
2005;
76
1211-1216
123 I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism.
Eur J Nucl Med Mol Imaging.
2008;
, DOI:
DOI: 10.1007/s00259-008-0777-2
2 receptor upregulation in Parkinson's disease: an [123 I]IBZM and [123 I]FP-CIT SPECT study.
Eur J Nucl Med Mol Imaging.
2007;
34
502-507
123 I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Synapse.
2001;
39
101-108
11 C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor.
J Neural Transm.
2006;
113
187-193
123 I]-FP-CIT SPECT imaging: the [123 I]-FP-CIT study group.
Mov Disord.
2000;
15
503-510
123 I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor.
Ann Neurol.
2003;
53
489-496
123 I]-FP / CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease.
Mov Disord.
2006;
21
510-514
123 I]-FP-CIT SPECT scan explorations improves diagnostic accuracy.
Mov Disord.
2006;
21
310-317
123 I]β-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.
Mov Disord.
2002;
17
518-523
123 I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
J Nucl Med.
2004;
45
1688-1693
123 I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.
Neurology.
1993;
43 (Suppl. 6)
S17-20
2 receptors, and glucose metabolism in corticobasal degeneration.
Mov Disord.
2006;
21
1724-1727
123 I-FP-CIT SPECT.
Eur J Nucl Med Mol Imaging.
2005;
32
1176-1185
123 I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.
Lancet Neurol.
2007;
6
305-313
18 F]-dopa-PET imaging in assessing movement disorders.
Radiol Clin North Am.
2005;
43
93-106
18 F]fluorodeoxyglucose and neuropsychological testing.
Exp Neurol.
2005;
191 (Suppl. 1)
S95-S103
11 C-DTBZ and 18 F-FDG PET measures in differentiating dementias.
J Nucl Med.
2005;
46
936-944
N -methyl11 C]meta-Hydroxyephedrine positron emission tomography in Parkinson's disease and multiple system atrophy.
Eur J Nucl Med Mol Imaging.
2003;
30
127-131
123 I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease.
Ann Nucl Med.
2004;
18
453-461
123 I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism.
Mov Disord.
2006;
21
1990-1994
123 I-MIBG scintigraphy in patients with essential tremor.
Mov Disord.
2006;
21
1235-1238
123 I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease.
Mov Disord.
2004;
19
1438-1445
123 I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease.
Brain.
2006;
129
1188-1193
swen.hesse@medizin.uni-leipzig.de
